Primary Amyloidosis Involvong the Heart: Clinical Observation

DOI: 10.47026/2413-4864-2021-4-60-72

UDC: 616.12-003.821
BBC: Р410.12+Р415.202.7

Opalinskaya I.V., Danilova G.V., Isaeva N.Yu., Petrova E.S., Busalaeva E.I., Vasilyeva N.P., Sergeev A.V.

Primary Amyloidosis Involvong the Heart: Clinical Observation

Keywords: cardiac amyloidosis, amyloid cardiomyopathy, heart failure, Bortezomib

Primary amyloidosis is a disease with a complex and not fully understood pathogenesis, which is characterized by a wide range of clinical manifestations. Light chain amyloidosis is the most common form of systemic amyloidosis. At this, the heart is the dominant target organ in systemic amyloidosis. Cardiac amyloidosis (amyloid cardiomyopathy) is most often manifested by diastolic heart failure resulting from restrictive cardiomyopathy. Therapy of amyloid cardiopathy includes optimal treatment of heart failure and chemotherapy. To reduce the symptoms of heart failure, diuretics are the main means, since other pathogenetic agents cannot be used due to hypotension and a possible decrease in cardiac output. With the introduction of new medicinal products into clinical practice, such as the proteosome inhibitor Bortezomib, the prognosis for patients has improved. However, amyloidosis remains a difficult disease to diagnose and treat.

References

Blagova O.V., Nedostup A.V., Sedov V.P. i dr. Klinicheskie maski amiloidoza s po-razheniem serdtsa: osobennosti diagnostiki na sovremennom etape [Clinical masks of amyloidosis with cardiac involvement: diagnostic features at the modern stage]. Rossiiskii kardiologicheskii zhurnal, 2017, vol. 142, no. 2, pp. 68–79. DOI: http://dx.doi.org/10.15829/1560-4071-2017-2-68-79.
Demko I.V., Pelinovskaya L.I., Mosina V.A. Kraposhina A.Yu., Gordeeva N.V., Solov’eva I.A., Ryazanov A. E. Sluchai pervichnogo amiloidoza s porazheniem serdtsa I perikarda v praktike kardiologa [A case of primary amyloidosis with heart and pericardial involvement in the practice of a cardiologist]. Rossiiskii kardiologicheskii zhurnal, 2017, vol. 142, no. 2 , 103–105.
Kozlov V.A., Sapozhnikov S.P., Golenkov A.V. Epidemiologiya amiloidoza (preobladanie etiologicheskogo myshleniya) [Epedemiology of amiloidosis (prevalance of etiological thinking)]. Patologicheskaya fiziologiya i eksperimental’naya terapiya, 2021. vol.65, no. 2, 94–108. DOI: 10.25557/0031-2991.2021.02.94-108.
Lysenko (Kozlovskaya) L.V., Rameev V.V., Moiseev SV. i dr. Klinicheskie rekomendatsii po diagnostike i lecheniyu sistemnogo amiloidoza [Clinical Practice Guidelines for the Diagnosis and Treatment of Systemic Amyloidosis]. Klinicheskaya farmakologiya i terapiya, 2020, vol. 29, no. 1, pp. 13–24.
Myasnikova R.P., Andreenko E.Yu., Kushunina D.V i dr. Amiloidoz serdtsa: Sovremennye aspekty diagnostiki i lecheniya (klinicheskoe nablyudenie) [Amyloidosis of the heart: Modern aspects of diagnosis and treatment (clinical observation)]. Klinicheskaya i eksperimental’naya khirurgiya. Zhurnal imeni akademika. B.V. Petrovskogo, 2014, vol. 6, no. 4, рр. 72–82.
Nikiforov V.S., Nikishchenkova Yu.V. Covremennye vozmozhnosti speckle tracking ekhokardiografii v klinicheskoipraktike [Modern possibilities of speckle tracking echocardiography in clinical practice]. Ratsionalnaya farmakoterapiya v kardiologii, 2017, vol. 13, no. 2, pp. 248–255.
Nonka T.G. Vozmozhnosti diagnostiki I lecheniya amiloidoza serdtsa [Possibilities of diagnosis and treatment of amyloidosis of the heart]. Klinicheskaya meditsina, 2015, 93, no. 4, pp. 66–73.
Rameev V.V., Kozlovskaya L.V., Rameeva A.S, Tao P.P., Moiseev S.V. Osobennosti evolyutsii i prognosticheskoe znachenie porazheniya serdtsa u bolnykh sistemnym AL-amiloidozom [Features of evolution and prognostic significance of heart damage in patients with systemic AL-amyloidosis]. Klinicheskaya farmakologiya i terapiya, 2019, vol. 28, no. 2, pp. 49–59.
Smirnova E.A., Abdurakhmanova E.K., Filonenko S.P. Sistemnyi al-amiloidoz: trudnosti diagnoza [Systemic al-amyloidosis: difficulties of diagnosis]. Rossiiskii mediko-biologicheskii vestnik imeni akademika I.P. Pavlova, 2016, vol. 24, no. 3, pp. 141–153.
Ezdekov I.Z. Udar v serdtse AL – amiloidoza. Klinicheskoe nablyudenie [A blow to the heart of AL – amyloidosis. clinical observation]. Protivorechiya sovremennoi kardiologii: spornye I nereshennye voprosy: sb.materialov VII Vseros. konf. [Proc. of 7^th Sci. Conf. «Contradictions of modern cardiology: controversial and unresolved issues»]. Samara, 2018, p. 157.
Jimenez-Zepeda V.H., Duggan P., Neri P. Bortezomib-containing regimens for the treatment of newly diagnosed and relapsed amyloid light chain amyloidosis: a sin-gle-center experience. Clin Lymphoma Myeloma Leuk, 2016, vol. 16, pp. 79–84. Available at: https://pubmed.ncbi.nlm.nih.gov/27101985.
Palladini G., Sachchithanantham S., Milani P. A European collaborative study of cy-clophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood, 2015, no. 126, pp. 612–615. Available at: https://pubmed.ncbi.nlm.nih.gov/25987656.
Rodney H.F., Kevin M.A., Ronglih L., Sharmila D. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. Journal of the American College of Cardiology, 2016, no. 12, pp. 6–7. Available at: https://pubmed.ncbi.nlm.nih.gov/2763412.
Sipe J.D., Benson M.D., Buxbaum J.N., Ikeda S.I., Merlini G., Saraiva M.J., Westermark P. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid., 2016, vol. 23, no. 4, pp. 209–213. DOI: 10.1080/13506129.2016.

About authors

Opalinskaya Irina V.: Candidate of Medical Sciences, Associate Professor, Department of Faculty and Hospital Therapy, Chuvash State University, Russia, Cheboksary (opalinskaya_irina@mail.ru; ORCID: https://orcid.org/0000-0002-5760-269X)

Danilova Galina V.: Resident of Department of Faculty and Hospital Therapy, Chuvash State University, Russia, Cheboksary (galiamyasnikova@yandex.ru; ORCID: https://orcid.org/0000-0003-4124-1241)

Isaeva Natalya Yu.: Resident of Department of Faculty and Hospital Therapy, Chuvash State University, Russia, Cheboksary (natalya231096@mail.ru; ORCID: https://orcid.org/0000-0002-2279-9517)

Petrova Ekaterina S.: Resident of Department of Faculty and Hospital the Therapy, Chuvash State University, Russia, Cheboksary (ekaterina1996.96@mail.ru; ORCID: https://orcid.org/0000-0002-9515-0639)

Busalaeva Elena I.: Candidate of Medical Sciences, Associate Professor, Department of Internal and Family Medicine, The Institute of Postgraduate Medical Education; Associate Professor of Faculty and Hospital Therapy Department, Chuvash State University, Russia, Cheboksary (busa-elena@yandex.ru; ORCID: https://orcid.org/0000-0001-7313-0365)

Vasilieva Nina P.: Candidate of Medical Sciences, Associate Professor, Department of Faculty and Hospital Therapy, Chuvash State University, Russia, Cheboksary (ninajur@yandex.ru; ORCID: https://orcid.org/0000-0002-0183-9436)

Sergeev Alexander V.: Candidate of Medical Sciences, Deputy Chief of Medical Affairs, Pathologist, Republican Bureau of Forensic Medical Examination of the Ministry of Health of Chuvashia; Associate Professor, Department of General and Clinical Morphology and Forensic Medicine, Chuvash State University, Russia, Cheboksary (sergeevav@rbsme.ru; ORCID: https://orcid.org/0000-0002-8230-8927)

Article link

Opalinskaya I.V., Danilova G.V., Isaeva N.Yu., Petrova E.S., Busalaeva E.I., Vasilyeva N.P., Sergeev A.V. Primary Amyloidosis Involvong the Heart: Clinical Observation [Electronic resource] // Acta medica Eurasica. – 2021. – №4. P. 60-72. – URL: https://acta-medica-eurasica.ru/en/single/2021/4/7/. DOI: 10.47026/2413-4864-2021-4-60-72.

Single article

Opalinskaya I.V., Danilova G.V., Isaeva N.Yu., Petrova E.S., Busalaeva E.I., Vasilyeva N.P., Sergeev A.V.